ETH ZURICH AND HOCOMA AWARDED FOR ARM EXOSKELETON TECHNOLOGY
13th March 2012
13th March 2012
Robotic neurorehabilitation therapy device wins European Technology Transfer Award
The successful collaboration between ETH Zurich and the Swiss medical technology company Hocoma was awarded with the 2012 Technology Transfer Award at the European Robotics Forum in Denmark last week. The world’s first commercially available robotic arm exoskeleton, the Armeo®Power, provides early rehabilitation for patients with severe neurological movement impairments. The most prestigious prize in European robotics is awarded annually for outstanding innovation and successful technology transfer among science and industry.
Hocoma was set up in 2000, as a spin-off of the Swiss University Hospital Balgrist. The company currently employs more than 110 people at its headquarters near Zurich, Switzerland and at its subsidiaries in the US and Singapore. Hocoma develops and produces therapy solutions for neurological patients with movement disorders caused by stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy or other neurological diseases and injuries as well as low back pain patients. The product range features devices for intensive locomotion therapy (Lokomat®), functional therapy of the upper extremities (Armeo®), early rehabilitation and patient mobilization (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo®). Hocoma’s products are applied successfully in clinics and research institutes worldwide. This medical technology company has received many awards, and was honored with the “Red Herring 100 Global Award” in January 2010, as one of the hundred most innovative companies worldwide. Hocoma generated a turnover of more than 27 million CHF in 2011. Dr. Gery Colombo is the CEO of Hocoma AG.